Published in N Engl J Med on February 06, 2003
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol (2010) 1.70
Management of low-grade cervical lesions in young women. CMAJ (2005) 1.69
Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol (2008) 1.59
The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol (2008) 1.57
Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol (2008) 1.35
Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol (2009) 1.29
Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol (2006) 1.24
A very rare case of HPV-53-related cervical cancer, in a 79-year-old woman with a previous history of negative Pap cytology. Clin Interv Aging (2014) 1.16
A review of methods for detect human Papillomavirus infection. Virol J (2012) 1.09
Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev (2011) 1.08
Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am (2007) 1.07
Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort. J Virol Methods (2007) 1.05
Genotype distribution of cervical human papillomavirus DNA in women with cervical lesions in Bioko, Equatorial Guinea. Diagn Pathol (2009) 1.04
Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis (2008) 1.01
Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol (2009) 0.95
Inverse association between methylation of human papillomavirus type 16 DNA and risk of cervical intraepithelial neoplasia grades 2 or 3. PLoS One (2011) 0.94
Biomarkers of cervical dysplasia and carcinoma. J Oncol (2011) 0.94
Assessment of high-risk human papillomavirus infections using clinician- and self-collected cervical sampling methods in rural women from far western Nepal. PLoS One (2014) 0.93
Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. Cancer Res (2010) 0.93
MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J Natl Cancer Inst (2014) 0.92
Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. J Mol Diagn (2007) 0.92
Risk factors for cervical precancer and cancer in HIV-infected, HPV-positive Rwandan women. PLoS One (2010) 0.91
Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women. Obstet Gynecol Sci (2013) 0.90
Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study. Mutat Res (2007) 0.90
Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN. Cancer Prev Res (Phila) (2014) 0.81
Invited commentary: Human papillomavirus infection and risk of cervical precancer--using the right methods to answer the right questions. Am J Epidemiol (2009) 0.81
The diversity of human papillomavirus infection among human immunodeficiency virus-infected women in Yunnan, China. Virol J (2014) 0.81
Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population. BMC Infect Dis (2005) 0.79
Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. J Zhejiang Univ Sci B (2017) 0.79
Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. Int J Cancer (2011) 0.79
Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda. Infect Agent Cancer (2014) 0.78
Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta. BMC Infect Dis (2013) 0.78
Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. Indian J Med Res (2016) 0.77
The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus. Clinics (Sao Paulo) (2013) 0.77
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol (2012) 0.77
Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China. J Clin Microbiol (2014) 0.76
When to test women for human papillomavirus. BMJ (2006) 0.76
Market survey predictions on the future of US Pap testing. Cytojournal (2009) 0.75
The prevalence and pattern of HPV-16 immunostaining in uterine cervical carcinomas in Ethiopian women: a pilot study. Pan Afr Med J (2011) 0.75
Analysis of the Determinants of Low Cervical Cancer Screening Uptake Among Nigerian Women. J Public Health Africa (2015) 0.75
Cervical Cancer Screening for the Reluctant - HPV Testing of Air-Dried Vaginal Discharge. Int J Biomed Sci (2006) 0.75
Urologic Dermatology: a Review. Curr Urol Rep (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol (2006) 3.08
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol (2007) 2.91
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol (2009) 2.74
Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol (2003) 2.71
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol (2007) 2.52
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol (2008) 2.51
Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst (2005) 2.47
Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res (2006) 2.33
Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,. Rev Panam Salud Publica (2004) 2.33
CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol (2007) 2.27
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2002) 2.24
Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst (2011) 2.18
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis (2013) 2.18
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine (2008) 2.13
Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol (2008) 2.08
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med (2005) 2.06
High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer (2007) 2.06
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol (2008) 1.96
The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis (2011) 1.87
Colposcopy at a crossroads. Am J Obstet Gynecol (2006) 1.84
A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst (2002) 1.83
Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol (2004) 1.82
Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res (2006) 1.82
Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One (2011) 1.80
A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev (2003) 1.80
Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet (2002) 1.78
Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol (2007) 1.74
Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol (2013) 1.73
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis (2015) 1.73
Stability of archived liquid-based cervical cytologic specimens. Cancer (2003) 1.70
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol (2006) 1.69
Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst (2002) 1.68
Identification of a novel human papillomavirus (HPV97) related to HPV18 and HPV45. Int J Cancer (2007) 1.68
Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res (2012) 1.68
Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res (2009) 1.67
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer (2009) 1.65
Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol (2011) 1.65
From India to the world--a better way to prevent cervical cancer. N Engl J Med (2009) 1.64
A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis (2007) 1.62
Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol (2009) 1.60
Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol (2008) 1.59
Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res (2006) 1.59
Screening and prevention methods for cervical cancer. JAMA (2009) 1.59
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis (2002) 1.58
Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev (2004) 1.56
Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation? Am J Clin Pathol (2008) 1.56
A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer (2008) 1.46
Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis (2006) 1.45
Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer (2012) 1.44
Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol (2003) 1.44
Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev (2003) 1.44
Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One (2010) 1.43
Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst (2004) 1.43
Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst (2012) 1.40
The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy. J Low Genit Tract Dis (2015) 1.39
Heterogeneity in CIN3 diagnosis. Lancet Oncol (2008) 1.38
The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer (2011) 1.38
Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst (2012) 1.38
Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev (2010) 1.36
A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis (2004) 1.36
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis (2013) 1.36
Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis (2009) 1.35
Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol (2008) 1.35
Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer (2010) 1.32